369 related articles for article (PubMed ID: 19528371)
1. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.
Jensen TO; Schmidt H; Møller HJ; Høyer M; Maniecki MB; Sjoegren P; Christensen IJ; Steiniche T
J Clin Oncol; 2009 Jul; 27(20):3330-7. PubMed ID: 19528371
[TBL] [Abstract][Full Text] [Related]
2. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
3. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
Salmi S; Siiskonen H; Sironen R; Tyynelä-Korhonen K; Hirschovits-Gerz B; Valkonen M; Auvinen P; Pasonen-Seppänen S
Melanoma Res; 2019 Jun; 29(3):237-247. PubMed ID: 30399061
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer.
No JH; Moon JM; Kim K; Kim YB
Gynecol Obstet Invest; 2013; 75(4):263-7. PubMed ID: 23595052
[TBL] [Abstract][Full Text] [Related]
6. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
7. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
8. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
10. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
Medrek C; Pontén F; Jirström K; Leandersson K
BMC Cancer; 2012 Jul; 12():306. PubMed ID: 22824040
[TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
12. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance.
Fujii N; Shomori K; Shiomi T; Nakabayashi M; Takeda C; Ryoke K; Ito H
J Oral Pathol Med; 2012 Jul; 41(6):444-51. PubMed ID: 22296275
[TBL] [Abstract][Full Text] [Related]
14. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
[TBL] [Abstract][Full Text] [Related]
15. Differential association of CD68
Tremble LF; McCabe M; Walker SP; McCarthy S; Tynan RF; Beecher S; Werner R; Clover AJP; Power XDG; Forde PF; Heffron CCBB
Br J Cancer; 2020 Nov; 123(10):1553-1561. PubMed ID: 32843682
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
17. CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood.
Krijgsman D; De Vries NL; Andersen MN; Skovbo A; Tollenaar RAEM; Møller HJ; Hokland M; Kuppen PJK
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824692
[TBL] [Abstract][Full Text] [Related]
18. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
19. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.
Knudsen TB; Ertner G; Petersen J; Møller HJ; Moestrup SK; Eugen-Olsen J; Kronborg G; Benfield T
J Infect Dis; 2016 Oct; 214(8):1198-204. PubMed ID: 27354366
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
